intermediate grade lymphoma
Summary: One of the three major prognostic groupings for non-Hodgkin lymphomas as proposed in the Working Formulation of the Non-Hodgkin's Lymphoma Pathologic Classification Project sponsored by the National Cancer Institute (1981). Lymphomas falling within this group have an intermediate survival potential.
- [Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases]Hui Qiang Huang
Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, PR China
Ai Zheng 23:448-51. 2004..Significantly higher response rate can be yielded by combined regimen such as FN, FMD, and FC, etc. The purpose of this study was to investigate the efficacy and toxicity of fludarabine-based regimen for patients with lymphoma in China...
- Clinicopathological characteristics and prognostic factors of primary gastrointestinal lymphoma: a 22-year experience from South ChinaMinrui Li
Division of Gastroenterology, The First Affiliated Hospital, Sun Yat Sen University Guangzhou 510080, P R China
Int J Clin Exp Pathol 7:2718-28. 2014..Univariate and multivariate analysis revealed that performance status, lactate dehydrogenase (LDH) level and histological type were independent prognostic factors for PGIL. ..
- Multicentric lymphoma in a giant anteater (Myrmecophaga tridactyla)Adrien W D Sanches
Veterinary Hospital, Laboratory of Veterinary Pathology, Universidade do Contestado, R Roberto Elhke, 85, Centro, Canoinhas, SC, CEP 89460 000, Brazil
J Zoo Wildl Med 44:186-8. 2013..The neoplasia was classified as a form of multicentric lymphohistiocytic lymphoma (Rappaport Classification) and as an intermediate grade lymphoma (National Cancer Institute Working Formulation).
- Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain?Mariano Provencio
Servicio de Oncologia Medica, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
Clin Transl Oncol 14:386-90. 2012..Little data is available concerning variations in the clinical characteristics of lymphoid neoplasms at presentation. We decided to investigate whether any variations in these characteristics had occurred in Spain during the last few years...
- Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma?P Mollee
Bone Marrow Transplant Service, Princess Margaret Hospital, Toronto, Canada
Bone Marrow Transplant 31:953-60. 2003..New approaches to allogeneic transplantation, including the use of matched-unrelated donors and reduced-intensity conditioning regimens, may expand the applicability of this potentially curative modality...
- [Gastric non-Hodgkin lymphoma: guidelines for the therapeutic approach]Marcello Bellini
Dipartimento di Chirurgia Generale e D Urgenza Università degli Studi di Napoli Federico II
Chir Ital 55:391-7. 2003..Patients with low and intermediate grade lymphoma (according to the working formulation) had a longer survival (83% and 71%, respectively) than patients ..
- 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphomaC I Chen
The University of Toronto Autologous Blood and Marrow Transplant Program, Princess Margaret Hospital, University Health Network, Toronto, Canada
Bone Marrow Transplant 30:885-91. 2002..We conclude that high-dose therapy with ABMT is appropriate for lymphoma patients even when disease reduction requires repeated numbers of salvage regimens...
- Autologous hematopoietic transplantation for low-grade lymphomasJ G Gribben
Department of Adults Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cytotherapy 4:205-15. 2002..transplantation (SCT) has become the treatment of choice for patients with relapsed chemo-sensitive intermediate grade lymphoma, but its role in the treatment of low-grade lymphomas and in selected patients in first remission ..
- [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy]Roberto Bettini
Universita dell Insubria, Ospedale di Circolo, Varese
Recenti Prog Med 94:494-500. 2003..We investigated whether the IPI also had prognostic value for NHL patients with a low grade malignancy or high grade malignancy according to the WF...
- Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisoneFausto Rossini
Hematology Unit, Ospedale S Gerardo, Via Donizetti 106, 20052 Monza MI, Italy
Cancer 100:350-5. 2004..In the CEOP regimen, epirubicin was substituted for doxorubicin to reduce cardiotoxicity...
- Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphomaJeanette K Doorduijn
Department of Hematology, Erasmus MC Rotterdam, The Netherlands
Haematologica 89:1109-17. 2004..We analyzed the costs of therapy and follow-up of patients with NHL treated with CHOP with or without G-CSF prophylaxis...
- Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphomaElizabeth A Chrischilles
Department of Epidemiology, College of Public Health, University of Iowa, Iowa City 52242, USA
Cancer Control 10:396-403. 2003....
- Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classificationMasatoshi Hasegawa
Department of Radiology and Radiation Oncology, Gunma University School of Medicine, Maebashi, Japan
Int J Radiat Oncol Biol Phys 57:172-6. 2003..To analyze the results of radiotherapy (RT) for malignant lymphoma of the orbit and to evaluate them compared with the World Health Organization (WHO) classification published in 2001...
- Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neckTakeshi Nishioka
Department of Radiology, Hokkaido University School of Medicine, Kita 15, Nishi 7, Kita ku, Sapporo 060 8648, Japan
Int J Radiat Oncol Biol Phys 60:847-52. 2004....
- [Treatment of moderate-grade and high-grade malignant lymphoma with autologous hematopoietic stem cell transplantation]An Lan Wang
Hunan Tumor Hospital, Changsha, Hunan, PR China
Ai Zheng 22:1317-20. 2003..The purpose of this study was to investigate the effectiveness of HDCT combined with radiotherapy supported by HSCT in treatment of poor- prognostic moderate-grade and high-grade malignant lymphoma...
- Orofacial non-Hodgkins lymphoma in NigeriansVincent Ifechukwukwu Ugboko
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, College of Health Sciences, Obafemi Awolowo University, Ile Ife, Nigeria
J Oral Maxillofac Surg 62:1347-50. 2004..In this study, we sought to determine the occurrence of primary non-Hodgkins lymphoma (NHL) in the oral and maxillofacial region among Nigerians...
- Splenic non-Hodgkin's lymphoma presenting as recurrent kidney stones -- an "incidentaloma"?Kaushik Doshi
Jamaica Hospital Medical Center, Jamaica, NY, USA
Proc West Pharmacol Soc 51:55-7. 2008..However, further investigation led to the discovery of splenic lymphoma, which was asymptomatic earlier but may have manifested symptoms that mimicked renal colic...
- Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single instituteMiyuki Akutsu
Division of Hematology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
Oncol Res 17:137-49. 2008..Further evaluation and prospective studies of the TCC-NHL-91 are warranted...
- Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphomaRoberto Rodriguez
Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California 91001, USA
Biol Blood Marrow Transplant 12:1326-34. 2006....
- MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomasA J M Ferreri
Medical Oncology Unit, San Raffaele H Scientific Institute, Universita Vita Salute San Raffaele, Milan, Italy
Neurology 66:1435-8. 2006..Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained...
- Primary lymphoma of the liver--a case reportS Chawla
Tata Main Hospital, Jamshedpur, Jharkhand
Indian J Pathol Microbiol 47:533-5. 2004..The case is being reported for its rarity and the clinical importance of recognizing such cases because of excellent prognosis...
- Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimensKirit M Ardeshna
Department of Haematology, University College London Hospitals, London, UK
Br J Haematol 130:363-72. 2005..This analysis indicates that patients with malignant lymphomas, who have PD on 1 degrees ST, are not rescued by subsequent salvage regimens. They should either be treated palliatively or novel approaches should be explored...
- Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomasS Monfardini
Division of Medical Oncology, Azienda Ospedale Universita, Padova
Ann Oncol 16:1352-8. 2005..The aim of this study was to evaluate the efficacy and tolerability of vinorelbine and prednisone in frail elderly patients with NHL...
- Diffuse primary non-Hodgkin's lymphoma of the cranial vaultK Aquilina
Department of Neurosurgery, Beaumont Hospital, Dublin, Eire
Br J Neurosurg 18:518-23. 2004..The other nine reported cases of primary skull vault lymphoma are reviewed. The diffuse vault infiltration as well as the multiple intracranial, scalp and temporalis muscle masses renders this case unique...
- A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling resultsB Ribba
Institute for Medical Biomathematics, 10 Hate ena Street, P O B 282, 60991 Bene Ataroth, Israel
Bull Math Biol 67:79-99. 2005..Simulation results imply that if the interval between successive drug applications is prolonged beyond a certain point, treatment will be inefficient due to effects caused by heterogeneous blood flow in the system...
- High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortalityPunit D Wadhwa
Department of Medicine, Comprehensive Cancer Center of the University Hospitals of Cleveland Case Western Reserve University, Cleveland, Ohio 44106, USA
Biol Blood Marrow Transplant 11:13-22. 2005..BEP with or without IFR is a highly effective and well-tolerated regimen in the relapsed/refractory lymphoma setting. It has low morbidity and transplant-related mortality and a low incidence (3%) of posttransplantation malignancy...
- Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphomaHuda Salman
Department of Oncology, Montefiore Medical Center, Bronx, NY 10461, USA
Am J Clin Oncol 26:338-43. 2003..Substitution of idarubicin for doxorubicin in this setting, therefore, is not associated with an improved response rate...
- First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trialJohn D Hainsworth
The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville, 37203, USA
Clin Lymphoma 4:36-42. 2003..This regimen provides a treatment option for elderly patients who are not considered candidates for standard CHOP/rituximab chemotherapy...
- High-dose chemotherapy and autologous bone marrow transplantation in diffuse intermediate- and high-grade non-Hodgkin lymphomaThierry Philip
Bone Marrow Transplant Department, Centre Leon Berard, 28 rue Laennec, 69008, Lyon, France
Crit Rev Oncol Hematol 41:213-23. 2002..Timing and epidemiology are reviewed before the various clinical situations (primary refractory partial responses, complete responses and relapses). The Lyon consensus conference held in 1998 has also extensively been used and quoted...
- External beam radiation therapy in the treatment of patients with extranodal stage IA non-Hodgkin's lymphomaJonathan H Briggs
Department of Radiation Oncology, University of Arizona Cancer Center, 1501 North Campbell Avenue, Tucson, AZ 85724, U S A
Am J Clin Oncol 25:34-7. 2002..External beam radiation therapy is a highly effective treatment for stage IA NHL found in extranodal sites...
- Limited efficacy of intensified preparative regimens and autologous transplantation as salvage therapy in high grade non-Hodgkin's lymphomaR S Stein
Department of Medicine, Vanderbilt University School of Medicine, and VA Medical Center, Nashville, TN 37232, USA
Leuk Lymphoma 40:521-8. 2001..Survival was significantly inferior to the survival observed in a concurrent series of patients with intermediate grade lymphoma, 34% +/- 6%, p < .05...
- Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignanciesM Beran
Department of Leukemia, Division of Medicine, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard Box 61, Houston, Texas 77030 4095, USA
Ann N Y Acad Sci 922:247-59. 2000..Topotecan combined with paclitaxel is promising in low-/intermediate-grade lymphomas. The activity of topotecan justifies further evaluation of topotecan-containing combination regimens, particularly in MDS/CMML and acute leukemias...
- High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant RegistryC D Williams
Department of Hematology, University College Hospital, London, United Kingdom
J Clin Oncol 19:727-35. 2001....
- A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHLI W Flinn
The Johns Hopkins University, Baltimore, Maryland, USA
Ann Oncol 11:691-5. 2000..The objectives of this study were to determine the maximum tolerated dose (MTD) of liposomal daunorubucin with CVP (COP-X) and the tolerability of the regimen in patients with indolent lymphoma...
- Radiation therapy in the treatment of lymphomaJ Yahalom
Memorial Sloan Kettering Cancer Center, and Radiation Oncology in Medicine, Cornell University Medical College, New York, NY, USA
Curr Opin Oncol 11:370-4. 1999..Recent studies established the following points: 1) For early-stage intermediate grade lymphoma, combined modality is the treatment of choice...
- Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignanciesI F Khouri
Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
J Clin Oncol 16:2817-24. 1998....
- Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group BD R Budman
Cancer and Leukemia Group B, Chicago, IL, USA
J Clin Oncol 15:3275-9. 1997....
- Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphomaRichard B Wilder
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 94:601-5. 2002....
- Clinical presentation and treatment of secondary orbital lymphomaBita Esmaeli
Section of Ophthalmology, Department of Plastic Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Ophthal Plast Reconstr Surg 18:247-53. 2002....
- Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)Douglas W Blayney
Wilshire Oncology Medical Group, Inc, Pasadena, CA, USA
J Clin Oncol 21:2466-73. 2003....
- [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma]Zhong Yu Yuan
Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, PR China
Ai Zheng 22:393-6. 2003..The study was performed to compare the efficacy and toxicity of CHO (without prednisone) and standard CHOP regimen...
- Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphomaL M Cunningham
The Western Australian Centre for Pathology and Medical Research, Perth, WA, Australia
Leuk Lymphoma 44:251-5. 2003..lymphoma (B-cell DLCL n = 46, other aggressive histologies n = 17), Hodgkin's disease (n = 44) or low/intermediate grade lymphoma (n = 46), compared to healthy controls...
- Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapySylvie Martinet
Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland
Int J Radiat Oncol Biol Phys 55:892-8. 2003..To assess the outcome and prognostic factors in patients with orbital lymphoma treated by radiotherapy (RT)...
- Prognostic factors in localized aggressive non-Hodgkin's lymphomaSuleyman Alici
Institute of Oncology, Istanbul University, Istambul, Turkey
Am J Clin Oncol 26:1-5. 2003..These factors need to be evaluated for analyzing the outcome of treatment and to identify better therapeutic strategies...
- Single institute experience of chemotherapy and adjuvant radiotherapy for localized aggressive non-Hodgkin's lymphoma: retrospective analysis of the clinical efficacy of radiation therapyTakeshi Kodaira
Department of Radiation Oncology, Aichi Cancer Center, Nagoya, Aichi, Japan
Am J Clin Oncol 25:612-8. 2002..Limited-field radiation may have possible advantages in toxicity if it does not lead to worsening of the outcome, although a conclusive result could not be obtained by the current analysis...
- Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group studyMichael Crump
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
Leuk Lymphoma 43:1581-7. 2002..Other doses and schedules combining topo I and II inhibitors, or topo I inhibitors with alkylating agents, should be explored with the addition of hematopoietic growth factors in this patient population...
- Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma: 100 month follow-upB Bolwell
Department of Hematology and Medical Oncology, Taussig Cancer Center, and Transplant Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk R32, Cleveland, Ohio 44195, USA
Bone Marrow Transplant 29:673-9. 2002..We conclude that patients with NHL treated with ABMT, if in CR 5 years post transplant, are at very low risk of relapse with extended follow-up, suggesting the possibility of cure for all histologies, including those with low grade NHL...
- Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)Joseph A Sparano
Albert Einstein Comprehensive Cancer Center Montefiore Medical Center, Bronx, NY, USA
Blood 100:1634-40. 2002..It is unlikely that infusional therapy as used in this study produces a 25% or greater relative improvement in FFS compared with standard therapy...
- [Syndrome of persistent generalized lymphadenopathy with development into a gastric lymphoma]E Aguilar Ligorit
, Servei Valencia de Salut, Hospital Clinic Universitari, Valencia
Sangre (Barc) 35:64-8. 1990..Sixteen months after diagnosis, he developed intermediate-grade lymphoma of the stomach. Partial response was achieved by chemotherapy, and the patient presented pulmonary and meningeal tuberculosis which led him to exitus...
- CLONOTYPIC PCR FOR MINIMAL RESIDUAL DISEASE IN LYMPHOMAAriela Noy; Fiscal Year: 2002..peripheral blood stem cell transplantation (PBSCT) in the setting of relapsed and refractory low and intermediate grade lymphoma. Finally, quantitative clonotypic PCR will be used to determine if a reservoir of clinically occult ..